Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FIGHT-302: pemigatinib versus gemcitabine + cisplatin in first-line FGFR2-rearranged cholangiocarcinoma
NL-OMON52434Phase 3Recruiting
- Sponsor
- Incyte
- Start
- Apr 2020
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in cholangiocarcinoma (CCA) comparing Pemigatinib with Gemcitabine + cisplatin (2 arms). Primary endpoint: Progression-free survival. Started Apr 2020; status: recruiting.
02
Drugs
pemigatinibgemcitabinecisplatin
03
Conditions
cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on NL-OMON52434.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52434.